Évaluation in vitro et in vivo de l’interférence de la biotine sur les dosages immunologiques réalisés sur Cobas 8000 e602®

Abstract

Biotin is increasingly used freely at high doses (>I0 mg) that can cause interference problems with immunoassays. The laboratory must control the impact of this interference. This paper aims to evaluate, in vitro, the level of interaction of the biotin using the Cobas 8000 e602® Roche Diagnostics™ on cardiac markers, thyroid status, gonadotrophin hormones, procalcitonin, folate and vitamin BI2.Also, to evaluate the impact, in vitro, of the biotin intake (5mg / 3 times a day) for 5 days on the thyroid blood status for healthy subjects and using Cobas e602® and Advia Centaur XP® Siemens™.The in vitro assessment of the interaction of the biotin is an underestimation of the results for the sandwich method assays and to an overestimation of the results in case of use of a competitive immunoassay method. A bias of more 10% was observed from a biotin concentration of 20 ng/mL for TnThs, TSH, FT4, 30 ng/mL for FT3 and PCT and above 50 ng/mL for other parameters.Results of our in vivo study reflects the decrease ofTSH and the increase of FT3 concentrations with an important difference between Cobas® and Centaur® which would lead us to assert the impact of biotin.If the results of the immunology assays performed on Cobas e602® may be affected when patient is treated with biotin with doses equal or greater than 5 mg, 3 times a day, this effect will be noticeable only for certain parameters like TSH, FT4, FT3, TnThs and PCT.